港股异动 | 中国抗体-B(03681)涨超8% SM03的BLA获受理 标志该新药产品即将步入全面收获期
中国抗体-B(03681)涨超8%，截至发稿，涨8.11%，报1.20港元，总市值12.42亿港元。
消息面上，中国抗体-B近期发布公告，中国国家药品监督管理局已受理公司旗舰产品SM03(Suciraslimab)用于治疗类风湿关节炎(RA)的生物制品许可申请(BLA),受理编号为CXSS2300072。该申请为公司成立以来首项提交的上市申请，而SM03为公司自主开发的产品，亦是全球首个用于治疗RA及其他自身免疫性疾病治疗的抗CD22单克隆抗体，采用与目前市面现有疗法截然不同的独特全新作用机理。
分析人士表示，SM03的BLA获受理，标志着该新药产品即将步入全面收获期，也将让市场对公司近年来的跨越式发展拥有更清晰的认知。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.